2-deoxy-ATP enhances contractility of rat cardiac muscle

M Regnier, AJ Rivera, Y Chen, PB Chase - Circulation research, 2000 - Am Heart Assoc
M Regnier, AJ Rivera, Y Chen, PB Chase
Circulation research, 2000Am Heart Assoc
To investigate the kinetic parameters of the crossbridge cycle that regulate force and
shortening in cardiac muscle, we compared the mechanical properties of cardiac trabeculae
with either ATP or 2-deoxy-ATP (dATP) as the substrate for contraction. Comparisons were
made in trabeculae from untreated rats (predominantly V1 myosin) and those treated with
propylthiouracil (PTU; V3 myosin). Steady-state hydrolytic activity of cardiac heavy
meromyosin (HMM) showed that PTU treatment resulted in> 40% reduction of ATPase …
Abstract
—To investigate the kinetic parameters of the crossbridge cycle that regulate force and shortening in cardiac muscle, we compared the mechanical properties of cardiac trabeculae with either ATP or 2-deoxy-ATP (dATP) as the substrate for contraction. Comparisons were made in trabeculae from untreated rats (predominantly V1 myosin) and those treated with propylthiouracil (PTU; V3 myosin). Steady-state hydrolytic activity of cardiac heavy meromyosin (HMM) showed that PTU treatment resulted in >40% reduction of ATPase activity. dATPase activity was >50% elevated above ATPase activity in HMM from both untreated and PTU-treated rats. Vmax of actin-activated hydrolytic activity was also >50% greater with dATP, whereas the Km for dATP was similar to that for ATP. This indicates that dATP increased the rate of crossbridge cycling in cardiac muscle. Increases in hydrolytic activity were paralleled by increases of 30% to 80% in isometric force (Fmax), rate of tension redevelopment (ktr), and unloaded shortening velocity (Vu) in trabeculae from both untreated and PTU-treated rats (at maximal Ca2+ activation), and F-actin sliding speed in an in vitro motility assay (Vf). These results contrast with the effect of dATP in rabbit psoas and soleus fibers, where Fmax is unchanged even though ktr, Vu, and Vf are increased. The substantial enhancement of mechanical performance with dATP in cardiac muscle suggests that it may be a better substrate for contractility than ATP and warrants exploration of ribonucleotide reductase as a target for therapy in heart failure.
Am Heart Assoc